Medwell Laboratories, operated within the framework of the New Generation Technology (NGT) incubator is focussed on developing therapies for managing mild to moderate chronic inflammatory disorders. Its portfolio comprises anti-inflammatory drugs, based on the company proprietary technology which is based on the mechanism of action as cyclooxygenase 2 (COX-2) and 5-Lipoxygenase (5-LOX) enzymes dual inhibition. Its lead candidate MW001, is currently at the end of the pre-clinical program and claims to have demonstrated potent antiinflammation effect on UC, RA and dermatitis animal models.